Regardless of the tumor types, immune cell infiltrates, TLS, PD-L1 expression in tumor cells or immune infiltrating cells, TMB, IFN signature and DNA mismatch-repair deficiency status have been shown to represent potential biomarkers of response to ICI in several cancer subtypes.40-44 In our cohort, SMARCA4-UT without TLS-positive tumor did not respond to ICI and had a very poor OS. The gene discussed is SMARCA4; the disease is neoplasm.